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Abstract
Objectives: To review the indications, contraindications and efficacy of vaccination in some special situations:
immunosuppression, prematurity, pregnancy and post-exposure situations.
Sources of data: Systematic review of articles published during the two last decades, found in MEDLINE, SciELO
and Lilacs databases; guidelines of Programa Nacional de Imunizaçıes (Brazilian National Immunization Program),
2001 to 2004, and of Programa Nacional de DST/AIDS (Brazilian National STD/AIDS Program), 2004. Abstracts
published in national and international pediatric and infectious disease congress annals during the last five years
were also consulted.
Summary of the findings: Some special situations, such as immunosuppression, prematurity, pregnancy and
exposure to infectious diseases increased the risk of diseases or adverse post-vaccination events. In these
situations, special vaccines or special vaccination schedules are indicated, or vaccines should be postponed or even
forbidden. In general, toxoid or inactivated vaccines can be used, considering the possibility of insufficient immune
response. For immunosuppressed patients, in accordance with the type of immunosuppression, live virus or bacterial
vaccines should be avoided, because of the risk of vaccine agent spread. Immunization should include not only the
patient, but his/her home and day-care contacts as well.
Conclusions: Knowledge about the schedule indicated for each situation improves the chances of better vaccine
protection and decreases the risk of adverse events. Immunosuppressed or immunodeficient patients whose post-
vaccine antibody titers are not available should be considered susceptible when exposed to infectious disease, and
all the available prophylactic measures should be implemented, even when the vaccination schedule is correct.
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Generally speaking, vaccination schedules are meant
for healthy individuals under normal life conditions. Some
special situations, however, place individuals at greater
risk of becoming ill or presenting with adverse post-
vaccine events and may require specific vaccines or
vaccine schemes, or even indicate postponement or
contraindication of vaccination.
As follows, we shall discuss some special situations in
which the usual vaccine scheme may be modified,
postponed or reinforced.
Pre-term newborns
Premature newborns, irrespective of gestational age
and birth weight, may receive vaccines in the same
scheme and doses used for full term children, except for
hepatitis B vaccine.1 Immunization with hepatitis B vaccine
at birth in premature newborns with birth weight under
2,000 g may determine low serum conversion rates; an
immunization schedule started at 30 or more days of life
determines a response similar to that obtained in full-term
newborns with birth weight over 2,000 g.1,2 Pre-term
newborns born to HbsAg-positive mothers or those born
to mothers whose HbsAg status is unknown must receive
vaccine against hepatitis B and specific hepatitis B
immunoglobulin (HBIG) within 12 hours of birth; if the
birth weight is under 2,000 g, another three doses of the
vaccine must be administered, the first of these at the
chronological age of 1 month.
Considering the possibility of prolonged hospitalizations
and the risk of invasive bacterial diseases, it is advisable
that pre-term newborns should receive pneumococcal
conjugate and meningococcal conjugate vaccines, as from
2 months of age; the immunogenicity, efficacy and safety
of these vaccines is similar for term and pre-term
newborns.3,4 There are no studies yet about the use of
rotavirus vaccine in premature infants.
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Yearly influenza immunization in autumn, as from the
age of 6 months, is particularly important for premature
infants with chronic pulmonary diseases.1 Vaccinating
family members and other persons that care for the baby
is useful, mainly for children under the age of 6 months.
Although there is no absolute contra-indication, the
Brazilian National Immunization Program (Programa
Nacional de Imunizaçıes) postpones the application of
BCG vaccine in newborns weighing less than 2,000 g at
birth.5
Natural breastfeeding and vaccination
No vaccine is contra-indicated or should be postponed
in breastfed children  the habitual vaccination scheme
must be used. There is also no contra-indication of
vaccination for breastfeeding mothers, as the majority of
live vaccine agents are not excreted in mothers milk.
Although attenuated vaccine virus may be transmitted to
the nursing infant through mothers milk in the case of
rubella vaccine, this does not determine additional risk  for
the child.6
Vaccination of pregnant women
It is desirable for a woman to be properly immunized
before pregnancy starts, but in the event that it is
necessary to vaccinate a pregnant woman, the medical,
legal and social risks of vaccination at this specific time of
life must be assessed, with a view to protecting the
pregnant woman and the newborn.7 Studies have been
conducted to seek vaccines which, when applied to pregnant
women, are able to induce protection against common and
serious diseases in the neonatal period, such as infections
by Streptococcus agalactiae and Streptococcus
pneumoniae.7,8
When indicated, vaccines containing inactivated viruses
or bacteria and toxoid may be applied in pregnant women
without risks to the fetus.9 However, live vaccines are
contraindicated during gestation, and women at a fertile
age must be guided to avoid pregnancy for 4 week after
vaccination with live virus vaccines.7,9  During a vaccination
campaign carried out in the state of Sªo Paulo, Brazil, in
the period from November 2001 to February 2002, 811
susceptible pregnant women were inadvertently vaccinated
against rubella and it was possible to collect blood samples
from 580 newborns of these susceptible women.10 The
congenital infection rate in these newborns was 4.7% (27/
580), but no child presented with clinical manifestations of
the congenital rubella syndrome. Greater risk of prematurity
and low birth weight was however, observed among the
infected newborn in comparison with non-infected newborns
of susceptible mothers and newborns of immune mothers
vaccinated during gestation.10
Vaccination with live vaccines to the home contacts of
pregnant mothers does not cause any risk to the pregnant
women. In situations in which the risk of acquiring disease
is greater (for the pregnant mother and/or for the fetus)
than the potential risk of the vaccine to the fetus, live oral
poliomyelitis vaccines, yellow fever and rabies vaccines
may be applied to pregnant women.1,11,12
Two vaccines should routinely be offered to pregnant
women: tetanus vaccine (with the purpose of preventing
neonatal tetanus through passive transplacental antibody
passage) and influenza vaccine.7,11,12 Pregnant women
that have completed the tetanus primary immunization
schedule must receive a booster dose during pregnancy,
in the event that the interval between the last dose of the
vaccine and pregnancy is longer than 5 years; non-
immunized pregnant women must receive three doses of
the vaccine starting as early as possible in the pregnancy;
partially vaccinated pregnant women must complete the
immunization schedule during gestation.5 The interval
between the first two doses is 2 months, and between the
second and third doses, 6 months. If there is no time to
apply the three doses of the vaccine during pregnancy, the
second dose must be applied at the latest 20 days before
the probable date of birth. Every time there is indication
of anti-tetanus vaccination, the combined tetanus-
diphtheria toxoid vaccine (dT) may be applied to take
advantage of the opportunity to protect against diphtheria,
since this disease still exists in an endemic form in the
country.
Influenza vaccine is recommended for healthy pregnant
women with more than 14 weeks of gestation, in the
months preceding the influenza season, to diminish the
increased risk of severe forms of influenza when pregnant
women are hospitalized for this disease; the vaccine is
safe throughout pregnancy.12,13
Hepatitis A and B vaccines may be applied to susceptible
pregnant women who are exposed during gestation.1,11
Pneumococcal vaccine may be applied to pregnant women
with risk of severe disease caused by S. pneumoniae.1
Inactivated polio vaccine (IPV), meningococcal vaccine
(conjugate or polysaccharide), oral attenuated or
inactivated typhoid fever vaccine can be applied during
gestation under special epidemiological conditions
(epidemics or journeys to areas where there is increased
risk of acquiring the disease).11,12
Taking advantage of the puerperal period to vaccinate
women susceptible to rubella, measles and other
preventable infections by the application of attenuated
live virus vaccines is a measure that has great impact on
public health.
Vaccinating the immunodeficient child
In the last 3 decades, there has been a considerable
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increase in conditions that determine immunodeficiency:
organ transplants, immunosuppressive chemotherapy,
prolonged use of corticosteroids, HIV infection, among
others. An increasing number of children and adults
survive these afflictions and become susceptible to
infectious agents, thus vaccines are measures capable of
actively protecting these patients.
Before indicating immunoprophylaxis for these
individuals, the following issues should be carefully
assessed: the intensity and duration of immunosuppression,
the risks of the disease to be avoided and the benefit (or
potential risks) of vaccination, in addition to previous
experience with the use of these immunobiologic products
in immunosuppressed patients. Generally speaking,
vaccines of inactivated and toxoid agents may be applied
in a similar manner to that recommended for healthy
individuals; live vaccines (viruses or bacteria) should be
avoided. Immunization of the household contacts of these
patients, especially with live virus vaccines, must also be
strictly assessed, considering the possibility of transmission
and spread of the vaccine virus, as in the case of OPV.1
Children undergoing immunoglobulin replacement therapy
may not have an adequate response to vaccination; the
time interval between immunoglobulin and vaccine
application must be assessed for each product used.12
Vaccinating the primary immunodeficient child
Immunization is an important active protection
instrument against infections in children with congenital
immunodeficiencies, but B cell and T cell deficiencies may
alter the effectiveness of vaccines and increase the risk of
adverse post-vaccine events. Among the congenital
immunodeficiencies, severe combined immunodeficiencies
are the most feared, as BCG vaccine complications are
frequently the first event to indicate this condition.14 BCG
vaccine in these children may determine systemic
dissemination of the vaccine bacillus or loco-regional
complications.15 With the purpose of preventing this BCG
vaccine complication, which may be fatal, children with a
family history suggestive of immunodeficiency (siblings
who died prematurely from undefined causes or whose
vaccine lesion does not progress normally) must have BCG
vaccination postponed until their immunocompetence has
been defined.
Oral poliomyelitis vaccine (OPV) (attenuated live virus)
must not be applied in children with congenital
immunodeficiencies, because of the increased risk of
developing paralytic poliomyelitis associated with
vaccination, in addition to continuing to excrete the virus
for long periods. Severely immunosuppressed patients
home contacts must also not receive this vaccine, because
of the risk of vaccine virus dissemination through feces,
which may last for up to 4 weeks.1 Other live virus
vaccines, such as measles/rubella/mumps vaccine, and
yellow fever vaccine are also contra-indicated for children
with T cell immunodeficiency, but there is no contra-
indication for applying these vaccines to these patients
household contacts, as the vaccine virus is not disseminated
from the vaccinated individual.1 Attenuated live vaccines
against measles, mumps and rubella may be considered
for children with slight antibody immunodeficiency.16
The varicella vaccine may be applied in children with
antibody immunodeficiency, but is contra-indicated in
those with cellular immunodeficiency.17 Vaccinating
immunodeficient childrens susceptible household contacts,
however, is an efficient way to diminish the risk of contact
for patients with altered immune response. In the event of
post-vaccine cutaneous rash development, the vaccinated
individuals must not come into contact with the
immunosuppressed patient.
Yearly influenza immunization (before winter) is safe
and is indicated in congenitally immunodeficient patients
who have greater influenza morbidity and mortality.13 The
vaccine must also be offered to the patients household
contacts, thereby reducing the risk of transmission.
Children with complement deficiency may receive all
the vaccines in the routine calendar; there is specific
indication for immunization against meningococci,
Haemophilus influenza type b (Hib) and pneumococci.18
Children with phagocytosis defects must not receive BCG
vaccine, but they may receive the other vaccines in the
routine calendar.19
The protective response obtained with immunization of
those congenital immune deficiency children may be
inadequate: the antibody titers obtained may be insufficient,
and they may drop more quickly than usual. Thus, even
though vaccinated, these patients may remain susceptible
to infectious diseases, which make it advisable to perform
serologic tests to assess the antibody levels obtained after
vaccination; additional or higher doses of vaccines may be
necessary and even so, the response obtained may not be
optimal. Taking all this into consideration, in the event of
exposure to infectious diseases, these patients must be
considered susceptible and passive immunization, if
available, must be indicated.16,17
Vaccinating the child with cancer
The cancer patient must be strictly assessed to verify
the immunosuppression conditions dependent on the
disease itself, the therapy that the patient is or was
submitted to and the risks of the disease one wants to
prevent. Live vaccines are formally contra-indicated, and
inactivated, sub-unitary, recombining, polysaccharide and
toxoid vaccines may be applied, although it is known that
the vaccine efficacy may be substantially reduced. The
immune response is usually adequate three months to 1
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year after chemotherapy has been suspended. When the
baseline disease is in remission, and immunosuppressive
therapy has been suspended for a period longer than 3
months, the use of live virus vaccines may be
considered.1,16
Under the following conditions, the vaccine against
varicella may be applied in patients with acute lymphoid
leukemia:1,16,17 remission for at least 1 year, peripheral
blood lymphocyte and platelet counts higher than 700/mm3
and 100,000/mm3, respectively. Two doses should be
applied with an interval of 8 weeks between them.
The influenza vaccine1 must be applied at least 3 to 4
weeks after chemotherapy has been interrupted and when
the peripheral granulocyte and lymphocyte counts are
higher than 1,000 cells/mm3. The recommendations for
vaccinating the contacts are the same as those made for
congenital immunodeficiencies.
Children with cancer are at greater risk of developing
invasive Hib disease than immunocompetent children. The
more intense and prolonged chemotherapy is, the worse
the vaccine response is, thus it is advisable for these
patients to receive the vaccine as early as possible after
diagnosis and preferably before chemotherapy.16 For
children under the age of 5 years, not previously vaccinated
or who received only one dose of the vaccines before they
were 12 months old, two doses of the conjugate vaccine
are recommended with an interval of 2 months between
the doses; those who received two doses of the vaccine
before they were 12 months old, must receive only one
additional dose of vaccine.1 Children over the age of 5
years, not previously vaccinated, must receive two doses
of the conjugate vaccine, separated by an interval of 1 or
2 months.
In spite of the increased risk of developing
Pneumococcus invasive disease, the pneumonococcal
vaccine may result in sub-optimal protective response
in patients with hematologic neoplasias; with the purpose
of obtaining protective antibody levels after vaccination,
the vaccine must be applied as early as possible after
diagnosis, before radiotherapy or chemotherapy
begins.20 Children under the age of 5 years must receive
7-valent conjugate vaccine; children from 2 to 5 years
of age that have never been vaccinated should receive
two doses of the conjugate vaccine with a 6 to 8 week
interval between them, after that, two doses of
polysaccharide vaccine: the first dose 6 to 8 weeks after
the conjugate vaccine, and the second dose 3 to 5 years
after the first polysaccharide vaccine.20 Children who
have had the complete vaccine schedule for their age
must receive a booster dose of the conjugate vaccine
and two doses of the polysaccharide vaccine with the
same interval as before.20 Children aged between 5 and
10 years receive two doses of polysaccharide vaccine
with an interval of 3 years between the doses; over the
age of 10 years, they require two doses of the vaccine
with an interval of 5 years between doses.20
The antibody titers against tetanus, diphtheria and
poliomyelitis may be low in cancer patients submitted to
chemotherapy; when chemotherapy ends, booster doses
of these vaccines must be applied in children and
adolescents who have completed the basic vaccination
schedule against these diseases.
Vaccination of children with Hodgkins disease
Patients with Hodgkins disease may have functional
asplenia as a result of the disease or be splenectomized
as part of the treatment, and are thus susceptible to
disseminated pneumococcal infections. Pneumococcal
vaccine must be applied as previously described. The
response is better if the vaccine is applied 10 to 14 days
before splenectomy or chemotherapy.16,19 Vaccine
applied during or soon after chemotherapy offers the
worst results, but the ability to respond with antibody
production is rapidly recovered, and may be considered
reasonable 3 months after chemotherapy ceases. Patients
who receive vaccine during chemotherapy must receive
an additional dose 3 months after chemotherapy ends.1
In these patients, there is also increased risk of
developing invasive Hib diseases, and the conjugate
vaccine against this agent must be applied.
Children with anatomic or functional asplenia
Anatomic or functional asplenia results in increased
risk of developing fulminating bacteremia with high
mortality rates.1 Pneumococci and Hib are the most
frequent agents, followed by meningococci, other
streptococci and E. coli. Pneumococcal conjugate vaccine,
meningococcal C conjugate vaccine and Hib vaccine are
indicated, in accordance with the same schedule
recommended for patients with neoplasias.21
Children submitted to bone marrow or solid
organ transplants
Vaccination of patients submitted to bone marrow or
solid organ transplants must take into consideration the
baseline disease, immunosuppressive therapy, donor
immunity, time elapsed after transplant and graft versus
host reaction.1 Pneumococcal infections are an important
cause of morbidity and mortality after bone marrow
transplant, and the risk is greater among patients who
present with graft versus host reaction. Protective response
is good if the vaccine is applied 6 to 12 months after the
transplant and the patient presents with no graft versus
host reaction; the response does not change when the
donor is vaccinated before the transplant.
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Hib is also an important cause of infection in bone
marrow transplant patients, but vaccinating the donor
before the transplant may induce a good antibody response
when the recipient is vaccinated 3 months after the
transplant. A single dose of Hib conjugate vaccine applied
12 months after the transplant, with a booster dose at 24
months, offers good protection, but it could be used in
children in a schedule of four doses at 3, 6, 12 and 24
months after the transplant.1
The effectiveness of the vaccine against influenza in
this group of patients depends on the space of time that
elapses between the transplant and vaccine application:
there is no antibody response when this interval is 6
months; 25% of patients respond with antibody production
when this interval is from 6 to 12 months, over 60% of
patients respond when vaccination is done 2 years after
the transplant.1 Two doses of vaccine with an interval of
1 month between them may be required for a good
response. All patients must receive vaccine in the autumn,
provided that they received transplants at least 6 months
previously.1 Vaccinating the transplant patients contacts,
including health personnel, is a more efficient measure
than vaccinating the patient.
Immunity against tetanus and diphtheria, as is the
case with other antibodies, is lost after the transplant. The
vaccine schedule with three doses of tetanus-diphtheria
vaccine (dT), with an interval of 1 month between doses,
starting 12 months after the transplant, is capable of
restoring immunity in practically all patients. Vaccinating
the donor before the transplant, followed by vaccinating
the recipient immediately after the transplant would
appear to favor the response of these antigens. However,
if a patient suffers tetanogenic injury in the first year after
the transplant, s/he must receive hyper-immune anti-
tetanus immunoglobulin (TIG), irrespective of having
received vaccine in the last three months or not.1
Transplanted patients should not receive poliomyelitis
live vaccine. When children are exposed to live vaccine
virus, by virtue of the routine vaccination of other children,
they must receive three doses of the inactivated virus
vaccine, although cannot be assured a protective response
in all patients.
Not a great deal is known about the immunogenicity of
the vaccine against hepatitis B in bone marrow or solid
organ transplant patients,22-24 but, considering the risk of
acquiring hepatitis B in blood transfusions, immunization
with three doses of the hepatitis B vaccine as from the 12th
month after the transplant is indicated. Whenever possible,
post-vaccine seroconversion must be assessed, and up to
three additional doses of vaccine must be applied in serum
negative individuals.1,22 Serum negative patients who are
submitted to solid organ transplants must be vaccinated
before the transplant. In the case of chronically dialyzed
patients or those with chronic hepatic disease, the vaccine
response may not be ideal, and after solid organ transplants,
only 5 to 15% of patient seroconvert, which justifies
vaccinating them before the transplant.
Whenever possible, vaccines against measles and
varicella must be applied at least 1 month before the
transplant procedure, since these diseases may determine
serious complications in transplant recipients. Measles/
mumps/rubella vaccine must be considered 24 months
after the transplant, at all times taking into account the
epidemiological situation of the disease in the region
where the patient is. Patients exposed to disease must
receive passive prophylaxis with immunoglobulin.
Varicella vaccine has been used in kidney transplant
children with encouraging results,25 but it has still not
been tested in bone marrow transplant recipients. The use
of specific varicella-zoster (VZIG) immunoglobulin is
indicated for susceptible patients who are exposed to the
disease.1
BCG vaccine must not be applied to patients submitted
to bone marrow or solid organ transplants.
Vaccination of the child receiving corticosteroid
therapy
The dose and duration of corticotherapy required to
induce immunosuppression in immunocompetent children
and adults is still under discussion. In addition to the dose,
the frequency, administration route and the underlying
disease that originated the corticosteroid therapy indication
are important. Doses equal to or higher than 2.0 mg/kg/day
of prednisone or 20 mg/day in children weighing over
10 kg (or the equivalent for other corticosteroids), for 14
or more days, have been considered sufficient to counter-
indicate live virus vaccines.1,2 The American Academy of
Pediatrics1 establishes an empirical guide for the application
of live virus vaccines in children without underlying
immunosuppressive disease on corticotherapy:
 The topical use of corticotherapy, either on the skin or
aerosol or intra-articular does not contra-indicate the
application of live virus vaccines, except if there is
clinical or laboratory evidence of immunodeficiency, in
which case immunization must be postponed for up to
1 month after therapy has been discontinued.
 The use of physiological or smaller doses than
2 mg/kg/day of prednisone (or equivalent) does not
contra-indicate live virus vaccines.
 Use of doses (daily or on alternate days) equal to or
higher than 2 mg/kg/day of prednisone (or equivalent)
for periods shorter than 14 days: They may receive live
virus vaccines immediately or, if possible, 2 weeks
after therapy has been suspended.
 The use of the above-mentioned doses for periods
longer than 14 days requires corticotherapy to be
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suspended for 1 month before the application of live
virus vaccines.
Children with underlying immunosuppressive disease,
who receive doses equal to or higher than 2 mg/kg/day of
prednisone daily or on alternate days, must not receive
live virus vaccines.
HIV-infected children, adolescents and adults
The ideal time to administer vaccines and the possible
risks or secondary adverse events of vaccine in patients
infected by HIV has not yet been well established. The
capacity of HIV-infected individuals to respond with
adequate and protective antibody titers after vaccination
depends on the degree of immunologic compromise at the
time of immunization; for this reason they must be
considered as possibly susceptible, even if adequately
vaccinated, unless serologic tests have confirmed the
presence of adequate antibody titers.1
In general, routine vaccination is safe and efficient
when applied to children without immunosuppression.
Serious complications resulting from immunization with
live vaccines in patients infected by HIV have been
described with BCG, oral polio and measles
vaccines.1,18,26-29
It is recommended that vaccines should be applied
soon after infection, when the immune response is still
adequate and when there is less risk of post-vaccine
adverse events. Patients with serious disease and severe
immunodepression must have their vaccination postponed
whenever possible, until some degree of immune
reconstitution is obtained after therapy. Vaccine efficacy,
considered insufficient before the use of potent combined
antiretroviral therapy (HAART),30 may be modified by the
therapy.
BCG vaccine is recommended at birth in countries
with high risk for tuberculosis, such as Brazil, but it is
contra-indicated in patients who already present with
immunosuppression or clinical signs of the disease.31
There are still no studies that prove the efficacy and
safety of BCG vaccine for protection against tuberculosis
in HIV infected children, which makes it difficult to
assess the risks and benefits of its application. Although
clinical experience has shown good safety of the vaccine
in asymptomatic children, regional lymphadenitis may
occur, and cases have been described of dissemination
of the vaccine bacillus in these children.32 As the vaccine
contains attenuated live mycobacteria, infected children
who present with immune reconstitution after HAART
has been instituted, may have infection by BCG
reactivated long after its application; this reactivation is
manifested as abscesses at the vaccine site or in
regional lymph nodes.33 The tuberculin test performed
6 to 12 months after BCG vaccination was not reactive
in over 90% of the Brazilian HIV-infected children.34
OPV can be applied to HIV-infected children,35 but
preference must be given to IPV, not only for the patients,
but for their family members and home contacts as well.
In Brazil it is possible to apply IPV in the special
immunobiologic reference centers (CRIE). Two cases of
post-vaccine paralytic poliomyelitis were described in HIV
infected children in Romania and Zimbabwe, but it is not
clear whether the occurrence of the paralytic accident in
these children was greater than that expected in the
general population not infected by HIV.28,29,36
Symptomatic HIV-infected children or those with severe
immunodeficiency must receive only IPV.31
Children born to HIV-infected mothers may present
reduced placental transfer of antibodies against measles,
and be susceptible to natural infection soon after birth.37
The antibody response after vaccination may be
diminished, particularly among symptomatic children
with immunosuppression.37,38 Measles vaccine applied
in isolation or in association with rubella and mumps
vaccines are safe, and its use has not been associated
with greater frequency of adverse events, even in
symptomatic individuals.36 Two cases of measles
pneumonitis after vaccination have been described: one
adult died24 and one child recovered.39 Considering the
risk of undesirable adverse events and less protective
response, it is recommended that the vaccine be avoided
in children with severe immunosuppression.1,40 HIV-
infected adults in our country are usually immune to
measles, but in the event that they are susceptible, the
vaccine may be applied when there is no severe
immunosuppression and there is significant risk of
acquiring the disease. If exposed to measles, patients
with symptomatic HIV infection, irrespective of their
vaccine status, must receive intramuscular standard
immunoglobulin in the first 6 days after contact, at the
dose of 0.5 mL/kg of weight, up to a maximum dose of
15.0 mL. If children with AIDS, who make regular use of
intravenous immunoglobulin, have been in contact with
measles, they do not need to make use of prophylactic
immunoglobulin, if the last dose of immunoglobulin was
administered less than 3 weeks before.1,41
No problems have been reported with rubella or its
vaccine in HIV-infected children and adolescents.
However, Brazilian HIV-infected children present with
lower antibody titers and greater chance of remaining
susceptible to disease after vaccination at 12 months of
age, when compared with seronegative controls,
especially when they already present with some degree
of immunosuppression at the time of vaccination.42
Additional doses of vaccine may diminish the contingent
of susceptible adolescents, which may indirectly increase
the chance of congenital rubella cases.
Varicella may be potentially serious in HIV-infected
children and adults. Two doses of the vaccine, with an
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interval of 3 months between them, may be applied to
asymptomatic or slightly symptomatic children infected
by HIV (clinical classification N1 or A1) and who present
a T CD4+ lymphocyte percentage higher than or equal to
25%.17,31,43 Children and adults susceptible to varicella
who are exposed to a household, school or in-hospital
contact case of varicella must receive VZIG intramuscularly
at a dose of 125 U for each 10 kg of weight, with a
maximum of 625 U, as quickly as possible after contact,
at most within the first 96 hours.1,41
The antibody production response against tetanus,
diphtheria and Hib would appear to be adequate after
primary vaccination in children receiving powerful
antiretroviral therapy;44 there are no contra-indications
for vaccination with DTP, dT and the conjugate vaccine
against Hib; they are not related to more frequent adverse
events and must be applied routinely in HIV+ children.
Considering the potential risk of serious bacterial infections
in HIV-infected patients, children over the age of 12
months who have not previously been vaccinated against
Hib must receive two doses of the vaccine with an interval
of 2 months between the doses. The antibody titers
against tetanus and diphtheria appear to diminish early in
HIV-infected children, particularly those with
immunosuppression;45 additional booster doses may be
necessary for these vaccines.45
The hepatitis B vaccine is safe for application to HIV-
infected children; but only 25 to 50% of vaccinated
patients present with protective antibodies;46,47 this
response is better in younger children without
immunosuppression. When the hepatitis B vaccine has not
been applied in the first year of life and the vaccine
schedule is started in symptomatic individuals, a double
dose of the vaccine must be applied. A fourth dose of the
vaccine must be contemplated.31,40
In Brazil, the hepatitis A vaccine is not available to all
HIV-infected children; it must be applied to susceptible
individuals who present with hepatopathy in a two-dose
schedule with an interval of 6 months between them.40
Research conducted at UNIFESP with children and
adolescents exposed to HIV revealed that the prevalence
of individuals susceptible to hepatitis A among adolescents
is greater than in the non-infected population48 and that
the vaccine is safe and efficient, protecting 100% of the
vaccinated HIV-infected children (without severe
immunosuppression).49 Considering that children with
AIDS receive antiretroviral therapy that is potentially
hepatotoxic, and that hepatitis A virus infection could
aggravate HIV infection, vaccine prophylaxis is important
for this group of patients.
HIV-infected children and adults must receive annual
doses of influenza vaccine, since they are at increased risk
of becoming ill and presenting with complications resulting
from the influenza. The pneumococcal conjugate vaccine
must be applied in the habitual schedule in children that
start vaccination in the first months of life (2, 4, 6 and 15
months). Booster doses with polysaccharide vaccine must
be applied at 24 and 60 months.29 Children from 12 to 15
months old with incomplete schemes, or those who have
not been vaccinated, receive two doses of conjugate
vaccine with an interval of 2 months between the doses
and booster doses with polysaccharide vaccine at 24 and
60 months. Children aged between 2 and 10 years receive
two doses of polysaccharide vaccine with an interval of 3
months between them. Children over the age of 10 years
receive two doses of polysaccharide vaccine with an
interval of 5 years between doses.
The efficacy and safety of the yellow fever vaccine in
HIV-infected patients has still not been established; it may
be applied as from the age of six months of life in endemic
areas of the disease, a situation in which the epidemiologic
risk justifies indication of the vaccine.40 According to the
Brazilian Ministry of Health guideline, individuals who
move to regions of high risk for the disease, and who do
not present with immunodeficiency or present it to a
moderate degree may receive the vaccine; individuals
with a severe degree of immunodeficiency must avoid
going to high risk regions and must avoid the vaccine.31
Post-exposure vaccination
Infectious disease control includes measures that aim
to control the dissemination of disease in the community
or in the home. In addition to compulsory notification of
some diseases to the epidemiologic surveillance system in
order to set control measures in motion, steps must be
taken to isolate the patient and prevent or attenuate the
disease with the use of antimicrobial agents,
immunoglobulin or serums and vaccines.
Here we shall deal with the infectious diseases for
which the use of vaccines may prevent infection and the
disease, even after exposure.
Mumps
The vaccine against mumps must be administered
soon after exposure in unvaccinated exposed children,
although there is no evidence that the vaccine prevents
the disease from appearing.50
Pertussis (whooping cough)
Non-immunized children under the age of 7 years, who
have been in contact with pertussis cases, must begin
immunization; additional doses of the vaccine to complete
the vaccine scheme must be applied in accordance with
the regular calendar. Prophylactic antibiotic therapy with
azytromicine, erythromycin or clarithromycin must be
performed with all contacts, particularly in those under 12
months of age.51
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Diphtheria
Children exposed to suspected cases of diphtheria,
in addition to the other measures (clinical follow-up,
antimicrobial agents, oropharynx material culture, etc.)
must receive the tetanus-diphtheria vaccine (infant 
DT, adult  dT or DTP, depending on age).52 Children
under the age of 7 years must start vaccination, if they
have not already been vaccinated, or complete their
vaccine calendar, if the scheme is not yet complete.
Previously immunized children over the age of 7 years
must receive a booster dose of dT, provided that they
have not received diphtheria vaccine in the last 5 years.
Hepatitis A
The hepatitis A vaccine has been successfully used in
post-exposure prophylaxis to control outbreaks and in
home and day care center contacts.53-55 It must be
applied as soon as possible after contact. The use of
human immunoglobulin is efficient in post-exposure
prophylaxis, when applied up to 2 weeks after contact.53
Hepatitis B
Post-exposure prophylaxis must be considered for
sexual contacts, home contacts and exposure to blood
and derivatives. Perinatal HBV transmission can be
prevented in 95% of the newborns to HBsAg+ mothers
by active and passive immuno-prophylaxis.56 Newborns
to HBsAg+ mothers must receive hyperimmune human
immunoglobulin (HBIG) and vaccine up to 12 hours after
delivery; vaccine and HBIG must be administered in
different anatomic sites. HBIG must be administered at
a dose of 0.5 mL, and the vaccine schedule must be
completed with additional doses of the vaccine at 30
days and 6 months; premature newborns weighing
under 2,000 g must receive a fourth dose of the vaccine.
Newborns to mothers with unknown serology for hepatitis
B must also receive vaccine and immunoglobulin soon
after birth.56
Children under the age of 12 months who do not
receive vaccination against hepatitis B and who are in
contact at home with HBsAg+ patients must receive HBIG
and vaccine; if one or two doses of the vaccine have
already been given, the vaccine schedule must be
completed.56 In sexual exposure, the informer must
receive HBIG at the dose of 0.06 mL/kg (maximum of
5 mL), up to 14 days from contact and also start a vaccine
schedule (0, 1 and 6 months).
Prophylaxis in situations of percutaneous accidents
with possibly infected blood depends on the exposed
persons vaccine status. Unvaccinated persons must
receive HBIG and vaccine; partially vaccinated persons
must complete the vaccine scheme.56
Meningococci
Careful clinical surveillance and chemo-prophylaxis,
preferably in the first 24 hours after exposure to cases
of meningococcemia, are mandatory for individuals of
any age.57 The immunization with meningococcal vaccine
may be done concurrently with chemo-prophylaxis in
outbreak situations, when the serogroup is known and
there is an efficient vaccine available, since secondary
cases may occur several weeks after the beginning of
the index case symptoms.57
Measles
The measles vaccine is useful to avoid the appearance
of the disease, if administered within 72 hours after
contact with a measles case. Therefore, this measure
should be implemented as soon as possible.1 Standard
immunoglobulin may be administered as a prophylactic
measure up to 96 hours after contact.
Varicella
In susceptible immunocompetent children, the
varicella vaccine, when administered up to 72 hours
(and possibly up to 120 hours) after contact, may
prevent or modify the disease.2,17 Susceptible children
at risk for developing serious forms of varicella, and who
cannot receive the vaccine, or who do not receive it in
time, must receive VZIG as quickly as possible, up to 92
hours after exposure.1
Tetanus
Non-immunized, or incompletely immunized individuals
with tetanogenic injuries must receive a dose of the
tetanus vaccine, and additional doses must be offered to
complete the primary immunization scheme.5 The need
for the simultaneous use of passive immunization depends
on the type of injury, the number of doses of the vaccine
already received, and the time elapsed since the last dose
of the vaccine.5
Rabies
In case of exposure to the rabies virus, immediate and
careful local treatment must be followed by passive
immunoprophylaxis (anti-rabies immunoglobulin) and
active immunoprophylaxis (vaccine). The vaccine (obtained
in cellular culture) must be applied preferably in the first
24 hours after exposure, but considering the severity of
the disease, it must be applied at any time after exposure58
in five doses on days 0, 3, 7, 14 and 28.5
Final considerations
Special situations, in which there is a possibility of
insufficient vaccine protective response or greater
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occurrence of potentially serious adverse post-vaccine
events, must be analyzed individually. Knowledge and use
of specific schemes for each situation increase the chance
of obtaining a better protective response and diminishing
the risk of vaccine related complications.
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